FDA decides against Lipitor-Zetia combo
The FDA rejected an application to market cholesterol drugs Lipitor and Zetia as a combination treatment because of a lack of manufacturing and stability data. Merck & Co., which developed Zetia with Schering-Plough, said it is reviewing the complete-response letter "to determine a new timetable for filing."
Wall Street Journal, The
| 11/2
This story published in FMI Pharmacy dailyLead on 11/03/2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|